Cargando…

Analysis of Viral and Host Factors on Immunogenicity of 2018, 2019, and 2020 Southern Hemisphere Seasonal Trivalent Inactivated Influenza Vaccine in Adults in Brazil

Annual vaccination against influenza is the best tool to prevent deaths and hospitalizations. Regular updates of trivalent inactivated influenza vaccines (TIV) are necessary due to high mutation rates in influenza viruses. TIV effectiveness is affected by antigenic mismatches, age, previous immunity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Capão, Artur, Aguiar-Oliveira, Maria L., Caetano, Braulia C., Neves, Thayssa K., Resende, Paola C., Almeida, Walquiria A. F., Miranda, Milene D., Martins-Filho, Olindo A.ssis, Brown, David, Siqueira, Marilda M., Garcia, Cristiana C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413331/ https://www.ncbi.nlm.nih.gov/pubmed/36016313 http://dx.doi.org/10.3390/v14081692

Ejemplares similares

Sera of patients infected by earlier lineages of SARS-CoV-2 are capable to neutralize later emerged variants of concern
por: Pauvolid-Corrêa, Alex, et al.
Publicado: (2022)

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China
por: Mo, Zhaojun, et al.
Publicado: (2017)

Impact of diabetes status on immunogenicity of trivalent inactivated influenza vaccine in older adults
por: Spencer, Sarah, et al.
Publicado: (2021)

Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancer
por: Kotecha, Rishi S., et al.
Publicado: (2015)

Comparative Immunogenicity of the 2014–2015 Northern Hemisphere Trivalent IIV and LAIV against Influenza A Viruses in Children
por: Ang, Jann Catherine, et al.
Publicado: (2019)

Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: an overview of systematic reviews
por: Carregaro, Rodrigo Luiz, et al.
Publicado: (2023)

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults
por: Beran, Jiří, et al.
Publicado: (2013)

The Safety and Immunogenicity of Trivalent Inactivated Influenza Vaccination: A Study of Maternal-Cord Blood Pairs in Taiwan
por: Lin, Shin-Yu, et al.
Publicado: (2013)

Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial
por: Nunes, Marta C, et al.
Publicado: (2020)

Morphology and morphogenesis of SARS-CoV-2 in Vero-E6 cells
por: Barreto-Vieira, Debora Ferreira, et al.
Publicado: (2021)

Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine
por: Montalban, Cecilia, et al.
Publicado: (2017)

Identification of SARS-CoV-2 and additional respiratory pathogens cases under the investigation of COVID-19 initial phase in a Brazilian reference laboratory
por: Matos, Aline da Rocha, et al.
Publicado: (2020)

Vaccine Mismatches, Viral Circulation, and Clinical Severity Patterns of Influenza B Victoria and Yamagata Infections in Brazil over the Decade 2010–2020: A Statistical and Phylogeny–Trait Analyses
por: da Costa, Jaline Cabral, et al.
Publicado: (2022)

Effectiveness of the 2010 and 2011 Southern Hemisphere trivalent inactivated influenza vaccines against hospitalization with influenza-associated acute respiratory infection among Thai adults aged ≥50 years
por: Dawood, Fatimah S, et al.
Publicado: (2014)

The Effect of Age and Recent Influenza Vaccination History on the Immunogenicity and Efficacy of 2009–10 Seasonal Trivalent Inactivated Influenza Vaccination in Children
por: Ng, Sophia, et al.
Publicado: (2013)

Evaluation of a rapid diagnostic test for measles IgM detection; accuracy and the reliability of visual reading using sera from the measles surveillance programme in Brazil, 2015
por: Warrener, Lenesha, et al.
Publicado: (2023)

Whole-Genome Characterization of a Novel Human Influenza A(H1N2) Virus Variant, Brazil
por: Resende, Paola Cristina, et al.
Publicado: (2017)

Immunogenicity and safety of an inactivated enterovirus 71 vaccine coadministered with trivalent split-virion inactivated influenza vaccine: A phase 4, multicenter, randomized, controlled trial in China
por: Chen, Yaping, et al.
Publicado: (2022)

Artificial Intelligence Applied to in vitro Gene Expression Testing (IVIGET) to Predict Trivalent Inactivated Influenza Vaccine Immunogenicity in HIV Infected Children
por: Cotugno, Nicola, et al.
Publicado: (2020)

Safety and immunogenicity of 3 seasonal trivalent influenza vaccines in the Chinese military
por: Gao, Dongqi, et al.
Publicado: (2016)

Transcutaneous delivery and thermostability of a dry trivalent inactivated influenza vaccine patch
por: Frolov, Vladimir G., et al.
Publicado: (2008)

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years
por: Kieninger, Dorothee, et al.
Publicado: (2013)

Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults
por: Stevanovic, Goran, et al.
Publicado: (2018)

Improvement of the Trivalent Inactivated Flu Vaccine Using PapMV Nanoparticles
por: Savard, Christian, et al.
Publicado: (2011)

Tolerability of trivalent inactivated influenza vaccine among pregnant women, 2015
por: Asavapiriyanont, Suvanna, et al.
Publicado: (2018)

A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months
por: Carmona Martinez, Alfonso, et al.
Publicado: (2014)

A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age
por: Pavia-Ruz, Noris, et al.
Publicado: (2013)

Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults
por: Cohen, Kristen W., et al.
Publicado: (2023)

A shortened interval between vaccinations with the trivalent inactivated influenza vaccine increases responsiveness in the aged
por: Kannan, Senthil, et al.
Publicado: (2015)

The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults
por: Ambrose, Christopher S., et al.
Publicado: (2010)

Immunogenicity and safety of Southern Hemisphere inactivated quadrivalent influenza vaccine: a Phase III, open-label study of adults in Brazil
por: Zerbini, Cristiano A.F., et al.
Publicado: (2016)

Immunogenicity and Safety of Trivalent Inactivated Influenza Vaccine: A Randomized, Double-Blind, Multi-Center, Phase 3 Clinical Trial in a Vaccine-Limited Country
por: Song, Joon Young, et al.
Publicado: (2011)

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study
por: Hu, Yuemei, et al.
Publicado: (2019)

Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a double blind, phase III randomized clinical trial in healthy Serbian adults
por: Stevanovic, Goran, et al.
Publicado: (2020)

Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®
por: Latreille-Barbier, Mathilde, et al.
Publicado: (2017)

Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine–only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants
por: Brickley, Elizabeth B, et al.
Publicado: (2018)

An HSV-2 Trivalent Vaccine Is Immunogenic in Rhesus Macaques and Highly Efficacious in Guinea Pigs
por: Awasthi, Sita, et al.
Publicado: (2017)

Whole-genome sequences of influenza A(H3N2) viruses isolated from Brazilian patients with mild illness during the 2014 season
por: Resende, Paola Cristina, et al.
Publicado: (2015)

PapMV nanoparticles improve mucosal immune responses to the trivalent inactivated flu vaccine
por: Rioux, Gervais, et al.
Publicado: (2014)

Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population
por: Tavares, Diana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bid078l42nmkafrkkqtr6g5hhi